Knight Therapeutics Inc.
GUD.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.44% | -11.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.44% | -11.31% | |||
| Cost of Revenue | 21.89% | -8.16% | |||
| Gross Profit | 33.38% | -15.72% | |||
| SG&A Expenses | 24.94% | 0.72% | |||
| Depreciation & Amortization | 17.49% | -13.07% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.03% | -8.53% | |||
| Operating Income | 31.27% | -82.46% | |||
| Income Before Tax | -3,958.42% | -104.94% | |||
| Income Tax Expenses | -19.94% | 11.87% | |||
| Earnings from Continuing Operations | -699.19% | -80.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -699.19% | -80.15% | |||
| EBIT | 31.27% | -82.46% | |||
| EBITDA | 45.28% | -8.71% | |||
| EPS Basic | -698.69% | -79.95% | |||
| Normalized Basic EPS | -48,700.00% | -100.13% | |||
| EPS Diluted | -776.26% | -80.61% | |||
| Normalized Diluted EPS | -48,700.00% | -100.13% | |||
| Average Basic Shares Outstanding | -0.01% | -0.89% | |||
| Average Diluted Shares Outstanding | -0.45% | -0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||